Sanofi sees sales grow by 9.9% at constant exchange rates in 2025[2][4]. This growth was supported by new drugs and vaccines, as well as strong sales of Dupixent[2]. Dupixent sales in Q4 2025 increased by 32.2% to €4.2 billion, a new quarterly high[2]. V Q3 2025 dosiahli predaje Dupixentu 4,2 miliardy eur s nárastom o 26,2 %, prvýkrát presahujúc hranicu 4 miliárd eur v jednom kvartáli[1][4]. Nevertheless, vaccine sales fell by 7.8% to €3.4 billion in Q3 2025 due to lower sales of influenza vaccines[1][4]. Dupixent's patent expires in 2031, with global sales expected to reach $25.4 billion[1]. Sanofi plans to grow sales by a high single-digit percentage in 2026[2].